Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 52-Week High - Should You Buy?

Key Points

• AMNEAL PHARMACEUTICALS shares hit a new 52-week high of $9.80, with the last traded price at $9.76 and a volume of 230,160 shares.
• Despite recent highs, Wall Street Zen downgraded the stock from a "strong-buy" to a "buy" rating, while Goldman Sachs issued a "buy" rating with a price target of $12.00.
• Insider trading activity revealed significant selling, with executives selling over 609,206 shares in the last three months, indicating potential confidence concerns among insiders.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) shares reached a new 52-week high during trading on Monday . The stock traded as high as $9.80 and last traded at $9.76, with a volume of 230160 shares traded. The stock had previously closed at $9.62.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group began coverage on Amneal Pharmaceuticals in a research report on Friday, June 6th. They issued a "buy" rating and a $12.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $11.60.

Amneal Pharmaceuticals Stock Performance

The company has a 50 day moving average of $8.83 and a two-hundred day moving average of $8.19. The stock has a market capitalization of $3.14 billion, a PE ratio of 1,001.00 and a beta of 1.19.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, EVP Andrew S. Boyer sold 279,244 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the sale, the executive vice president owned 152,426 shares in the company, valued at approximately $1,429,755.88. The trade was a 64.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jason B. Daly sold 22,000 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total value of $199,100.00. Following the sale, the executive vice president owned 10,606 shares in the company, valued at approximately $95,984.30. The trade was a 67.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 609,206 shares of company stock valued at $5,700,625 in the last 90 days. Corporate insiders own 26.56% of the company's stock.

Institutional Trading of Amneal Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in Amneal Pharmaceuticals by 5,975.0% during the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock valued at $26,000 after purchasing an additional 3,107 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Amneal Pharmaceuticals during the 1st quarter valued at about $31,000. Amalgamated Bank grew its stake in Amneal Pharmaceuticals by 33.0% during the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after purchasing an additional 1,367 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Amneal Pharmaceuticals during the 4th quarter valued at about $52,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Amneal Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,107 shares of the company's stock valued at $98,000 after purchasing an additional 1,735 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.